Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

524
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
524
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aging reprograms the functional, epigenetic, and metabolic landscape of macrophages.

Research square·2026
Same author

Macrophage-Centric Phenotypic Screening Identifies Tetrazolone-Based HDAC6 Inhibitors That Reprogram the Tumor Immune Microenvironment and Improve Immune Checkpoint Blockade.

Journal of medicinal chemistry·2026
Same author

The voice of the plateau: a qualitative interview study of student management and educational practices in higher education in Xizang Autonomous Region.

Frontiers in psychology·2026
Same author

Low maternal folic acid during pregnancy exacerbates ectopic fat accumulation in the liver and muscle of male offspring.

Diabetes research and clinical practice·2026
Same author

Expression of endogenous retroviral elements is associated with extracellular matrix remodeling in prostate cancer.

Mobile DNA·2026
Same author

An Empirical Dietary Inflammatory Pattern and Fecundability in a Multiethnic Asian Preconception Cohort.

The Journal of nutrition·2025

Related Experiment Video

Updated: Jul 2, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.3K

Targeting HDAC6 improves anti-CD47 immunotherapy.

Maria Gracia-Hernandez1, Ashutosh S Yende2, Nithya Gajendran3

  • 1Department of Biochemistry and Molecular Medicine, The George Washington University, Washington, DC, USA.

Journal of Experimental & Clinical Cancer Research : CR
|February 28, 2024
PubMed
Summary

Histone deacetylase 6 inhibitors (HDAC6is) enhance macrophage phagocytosis and potentiate CD47 immune checkpoint blockade therapy for melanoma. This study reveals HDAC6

Keywords:
CD47Histone deacetylasesImmunotherapyMacrophagesMelanomaNexturastat APhagocytosis

More Related Videos

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation
11:06

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation

Published on: September 20, 2017

6.2K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
00:06

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.9K

Related Experiment Videos

Last Updated: Jul 2, 2025

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
08:46

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

53.3K
Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation
11:06

Genome-wide Analysis of HDAC Inhibitor-mediated Modulation of microRNAs and mRNAs in B Cells Induced to Undergo Class-switch DNA Recombination and Plasma Cell Differentiation

Published on: September 20, 2017

6.2K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
00:06

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.9K

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • CD47, an immune checkpoint, is overexpressed in cancer cells, inhibiting macrophage phagocytosis via SIRPα interaction.
  • CD47 blockade shows promise in hematological cancers but has limited efficacy in solid tumors like melanoma.
  • Histone deacetylase 6 inhibitors (HDAC6is) possess immunomodulatory properties, yet their role in the CD47/SIRPα axis is unclear.

Purpose of the Study:

  • To investigate the role of HDAC6 in regulating the CD47/SIRPα axis and macrophage phagocytosis.
  • To evaluate the therapeutic potential of HDAC6 inhibition in combination with CD47 blockade for melanoma treatment.

Main Methods:

  • Utilized bone marrow-derived macrophages and cell lines to assess HDAC6is' effects on macrophage phenotype and phagocytosis.
  • Investigated CD47/SIRPα axis modulation and phagocytosis using murine and human melanoma cells and macrophages.
  • Conducted in vivo studies with melanoma mouse models to evaluate the antitumor activity of Nexturastat A combined with anti-CD47 or anti-SIRPα antibodies.

Main Results:

  • HDAC6 inhibition promoted antitumoral M1 macrophage polarization and reduced protumoral M2 phenotype.
  • HDAC6 inhibition decreased SIRPα expression, increased pro-phagocytic signals, and downregulated CD47 on melanoma cells.
  • Combined HDAC6 inhibition and anti-CD47 therapy enhanced macrophage phagocytosis and in vivo antitumor activity in melanoma models.

Conclusions:

  • HDAC6 plays a critical role in regulating macrophage phagocytosis and innate immunity.
  • HDAC6 inhibitors can potentiate CD47 immune checkpoint blockade strategies for cancer therapy.
  • Combination therapy with HDAC6is and anti-CD47 antibodies demonstrates significant antitumor activity in melanoma.